An estimated 2.8 million people worldwide are living with multiple sclerosis (MS), according to the National MS Society.

Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when started earlier.

With March being MS Awareness Month, we sat down with Everclear’s Art Alexakis, who was diagnosed with the chronic autoimmune disease nearly 10 years ago.

A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...

Some days I can bear to dance, others I fear the wheelchair,” Applegate writes in her new memoir, “You with the Sad Eyes.” ...

Thomas Leist, MD and Darin Okuda, MD provide insight into first-line treatment selection for MS and the patient factors involved. Maria Lopes, MD, MS discusses payer considerations and challenges in ...

Liver-related side effects have led some analysts to question fenebrutinib’s prospects, even though the drug has now cleared Phase 3 studies in multiple forms of the disease.

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

OMAHA, Neb. (WOWT/Gray News) - A Nebraska woman has become the first patient in the world to undergo a groundbreaking new treatment for multiple sclerosis. Seven years ago, Jan Janisch-Hanzlik began ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Panelists discuss how payers can evaluate BTK inhibitors by considering specific MS phenotypes and FDA indications rather than applying traditional step therapy protocols that may delay optimal ...

"The observed differential effects of high-efficacy disease-modifying agents across sexes underscore the importance of sex-specific considerations in making treatment decisions to personalize care in ...